Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis

New England Journal of Medicine

Volumn 367, Issue 25, 2012, Pages 2385-2395

  De Benedetti, Fabrizio ^a   Brunner, Hermine I ^e   Ruperto, Nicolino ^b   Kenwright, Andrew ^f   Wright, Stephen ^f   Calvo, Inmaculada ⁱ   Cuttica, Ruben ^k   Ravelli, Angelo ^b,c   Schneider, Rayfel ^m   Woo, Patricia ^g   Wouters, Carine ⁿ   Xavier, Ricardo ^p   Zemel, Lawrence ^q   Baildam, Eileen ^h   Burgos Vargas, Ruben ^r   Dolezalova, Pavla ^s   Garay, Stella M ^l   Merino, Rosa ^j   Joos, Rik ^o   Grom, Alexei ^e   Wulffraat, Nico ^t   Zuber, Zbigniew ^u   Zulian, Francesco ^d   Lovell, Daniel ^e   Martini, Alberto ^b,c   more..

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f ROCHE PRODUCTS LTD   (United Kingdom)

^g GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^h ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^k HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

^l Hospital de Ninos Sor Maria Ludovica   (Argentina)

^m HOSPITAL FOR SICK CHILDREN   (Canada)

ⁿ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^o GHENT UNIVERSITY HOSPITAL   (Belgium)

^p HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^q Division of Pediatric Infectious Diseases   (United States)

^r UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^s CHARLES UNIVERSITY   (Czech Republic)

^t UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^u Wojewodzki Specjalistyczny Szpital Dzieciecy Sw Ludwika ^*  (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TOCILIZUMAB;

ADOLESCENT; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHOPNEUMONIA; CHICKENPOX; CHILD; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FEVER; FRACTURE; GASTRITIS; GASTROENTERITIS; HEADACHE; HERPES ZOSTER; HIP DISLOCATION; HUMAN; HYPERFERRITINEMIA; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; THROMBOCYTOSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

EID: 84871318830     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1112802     Document Type: Article

References (32)

1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2. (Pubitemid 38160763)
2. Lomater C, Gerloni V, Gattinara M, Mazzotti J, Cimaz R, Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000;27:491-6. (Pubitemid 30095486)
3. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
4. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849-57.
5. Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25.
6. Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41.
7. Gattorno M, Piccinni A, Lasigliè D, et al. The pattern of response to anti-interleukin- 1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008;58:1505-15. (Pubitemid 351705940)
8. Lequerré T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008;67:302-8. (Pubitemid 351281262)
9. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54.
10. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25:203-7.
11. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158-63.
12. De Benedetti F, Pignatti P, Gerloni V, et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 1997;24:1403-9. (Pubitemid 27353389)
13. De Benedetti F, Alonzi T, Moretta A, et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I: a model for stunted growth in children with chronic inflammation. J Clin Invest 1997;99:643-50. (Pubitemid 27097665)
14. De Benedetti F, Rucci N, Del Fattore A, et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006;54:3551-63. (Pubitemid 44737167)
15. Cazzola M, Ponchio L, De Benedetti F, et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996;87:4824-30. (Pubitemid 26162385)
16. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006. (Pubitemid 351389534)
17. Ruperto N, Martini A. Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child 2011;96:596-601.
18. Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002;29:1058-64. (Pubitemid 34493514)
19. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis: Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9. (Pubitemid 30151920)
20. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9. (Pubitemid 27430130)
21. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-9. (Pubitemid 24371878)
22. Ruperto N, Ravelli A, Pistorio A, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries: review of the general methodology. Clin Exp Rheumatol 2001;19:Suppl 23:S1-S9. (Pubitemid 33730178)
23. Ruperto N, Martini A. Quality of life in juvenile idiopathic arthritis patients compared to healthy children. Pisa, Italy: Pacini, 2001.
24. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4. (Pubitemid 39453253)
25. European Medicines Agency. ICH Topic E 2 A: clinical safety data management: definitions and standards for expedited reporting: step 5 (http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500002749.pdf).
26. Strippoli R, Carvello F, Scianaro R, et al. Amplification of the response to tolllike receptor ligands by prolonged exposure to interleukin-6 mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum 2012;64:1680-8.
27. Padeh S, Laxer RM, Silver MM, Silverman ED. Primary pulmonary hypertension in a patient with systemic-onset juvenile arthritis. Arthritis Rheum 1991;34:1575-9.
28. Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2012 November 8 (Epub ahead of print).
29. Spiegel LR, Schneider R, Lang BA, et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 2000;43:2402-9.
30. Russo R, Katsicas M. Patients with early-onset systemic juvenile idiopathic arthritis show more inflammation and worse outcome. Pediatr Rheumatol 2011;9:Suppl 1:O18.
31. Hashkes PJ, Wright BM, Lauer MS, et al. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum 2010;62:599-608.
32. McInnes I, Lee JS, Wu W, et al. MEASURE: a translational, randomized, placebo (PBO)-controlled study to evaluate the effects of tocilizumab (TCZ) on parameters of lipids and inflammation. Presented at the European League against Rheumatism 2011 Congress, London, May 25-28, 2011. abstract.